Treatment of Hyperactive Children With Monoamine Oxidase Inhibitors: I. Clinical Efficacy

Archives of General Psychiatry

Volumn 42, Issue 10, 1985, Pages 962-966

  Zametkin, Alan ^a,c   Rapoport, Judith L ^a   Murphy, Dennis L ^a   Linnoila, Markku ^b   Ismond, Deborah ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLORGYLINE; DEXAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; TRANYLCYPROMINE;

ADVERSE DRUG REACTION; ANOREXIA; ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FATIGUE; HUMAN; HYPERACTIVITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SLEEP; THERAPY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PLATELETS; BLOOD PRESSURE; CHILD; CLINICAL TRIALS; CLORGYLINE; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; HUMANS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PULSE; SLEEP STAGES; TRANYLCYPROMINE;

EID: 0021967020     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1985.01790330042005     Document Type: Article

References (34)

1. Rapoport J, Buchsbaum M, Zahn T, Ludlow C, Weingartner E, Mikkelsen E: Dextroamphetamine: Cognitive and behavioral effects in normal and hyperactive children and normal adult men. Arch Gen Psychiatry 1980;37:933-946.
2. Glowinski J, Axelrod J, Iverson L: Regional studies of catecholamines in the rat brain: IV. Effects of drugs on the disposition and metabolism of 3H-norepinephrine and 3H-dopamine. J Pharmacol Exp Ther 1966;153:3-41.
3. Sporny L, Gorog P: Investigations into the correlations between monoamine oxidase inhibition and other effects due to methylphenidate and its stereoisomers. Biochem Pharmacol 1961;8:263-286.
4. Axelrod J: Amphetamine: Metabolism, pharmacological disposition and its effect on catecholamine storage, in Costa E, Garratini S (eds): International Symposium on Amphetamines and Related Compounds. New York, Raven Press, 1970, pp 206-207.
5. Carlsson A, Fuxe K, Hamberger B, Lindvist M: Biochemical and histochemical studies on the effects of impramine-like drugs and (±)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol Scand 1966;67:481-497.
6. Ferris R, Tange F, Maxwell R: A comparison of the capacities of isomers of amphetamine, deoxypipradol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 1972;181:407-416.
7. Glowinski J, Axelrod J: Effects of drugs on the uptake, release, and metabolism of 3H-norepinephrine and 3H-dopamine. J Pharmacol Exp Ther 1966;153:3-41.
8. Rapoport J, Ferguson B: Biological utilization of the hyperkinetic syndrome. Dev Med Child Neurol 1981;23:667-687.
9. Frommer EA: Treatment of childhood depression with antidepressant drugs. Br Med J 1967;1:729-732.
10. Kelly D, Guirguis W, Frommer E, Mitchell-Heggs N, Sargeant W: Treatment of phobic states with antidepressants. Br J Psychiatry 1970; 116:387-398.
11. Wood D, Reimherr F, Wender P: The use of L-deprenyl in the treatment of attention deficit disorder, residual type. Psychopharmacol Bull 1983;19:627-629.
12. Wender P, Wood D, Reimherr F, Word M: An open trial of pargyline in the treatment of attention deficit disorder-residual type. Psychiatry Res 1983;9:329-336.
13. Conners CK: A teacher rating scale for use in drug studies with children. Am J Psychiatry 1969;126:152-156.
14. Conners C: Rating scales for use in drug studies with children. Psychopharmacol Bull (special issue), 1973, pp 59-60.
15. Goyette CH, Conners CK, Ulrich RF: Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol 1978;6:221-236.
16. Pharmacotherapy of children. Psychopharmacol Bull (special issue), 1973, p 221.
17. Murphy DC, Wright C, Buchsbaum MS, Nichols A, Costa JL, Wyatt RJ: Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time. Biochem Med 1976;16:254-265.
18. Dunnett CW: New tables for multiple comparisons with a control. Biometrics 1964;20:482-491.
19. Lipper S, Murphy D, Slater S, Buchsbaum M: Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacology 1979;62:123-128.
20. Roy B, Murphy D, Lipper S, Siever L, Alterman I, Jimerson D, Lake C, Cohen M: Cardiovascular effects of the selective monoamine oxidase inhibiting antidepressant clorgyline: Correlations with clinical responses and changes in catecholamine metabolism. J Clin Psychopharmacol, in press.
21. Cohen R, Pickar D, Garrett D, Lipper S, Gillin C, Murphy D: REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacology 1982;78:137-140.
22. Foldes A, Costa E: Relationship of brain monoamine and locomotor activity of rats. Biochem Pharmacol 1975;24:1617-1621.
23. Schildkraut J: Tranylcypromine: Effects on norepinephrine metabolism in rat brain. Am J Psychiatry 1970;126:925-931.
24. Reigle TG, Orsulak PJ, Avni J, Platz P, Schildkraut J: The effects of tranylcypromine isomers on norepinephrine-3H metabolism in rat brain. Psychopharmacology 1980;69:193-199.
25. Murphy DL: Substrate-selective monoamine oxidase: Inhibitors, tissue, species and functional differences. Biochem Pharmacol 1978;27:1889-1893.
26. Zirkle CL, Kaiser C: Monoamine oxidase inhibitors, in Gordon M (ed): Psychopharmacology Agents. New York, Academic Press Inc, 1964, vol 1, pp 455-554.
27. Lee WC, Shin Y, Shideman FE: Cardiac activities of several monoamine oxidase inhibitors. J Pharmacol Exp Ther 1961;133:180-185.
28. Strada SJ, Sulser F: Effect of monoamine oxidase inhibitors on metabolism in vivo release of 3H-norepinephrine from the hypothalamus. Eur J Pharmacol 1972;18:303-308.
29. Lai J, Leung T, Guest J, Lim L, Davison A: The monoamine oxidase inhibitors, clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin rat brain synaptosomal preparations. Biochem Pharmacol 1975;24:1617-1621.
30. Langer D, Rapoport J, Ebert M, Lake CR, Nee L: Pilot trial of mianserin hydrochloride for childhood hyperactivity, in Shopsin B, Greenhill L (eds): The Psychobiology of Childhood: Profiled in Current Issues. Jamaica, NY, Spectrum Publications, in press.
31. Garfinkel B, Wender P, Sloman L, O'Neil J, Golombek H: Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry 1983;2:343-348.
32. Rapoport J, Bradbard G, Riddle D, Brooks E: Imipramine and methylphenidate treatments of hyperactive boys. Arch Gen Psychiatry 1974;30:789-793.
33. Brown G, Ebert M, Mikkelson E, Buchsbaum M, Bunney W: Dopamine agonist piribedil in hyperactive children. Read before the American Academy of Child Psychiatry, Chicago, May 17, 1979.
34. Langer D, Rapoport J, Brown L, Ebert M, Bunney W: Behavioral and cognitive effects of Sinemet in hyperactive boys. J Am Acad Child Psychiatry 1982;21:10-19.